CoreBone, Medicortex, iOmx Therapeutics
CoreBone Raises $3.7M in Funding
CoreBone, a Tel Aviv, Israel-based company that produces bioactive, coral-based bone graft material, raised $3.7m in funding.
The Guangzhou Sino-Israel Biotech Investment Fund (“GIBF”), which focuses on introducing Israeli medical technologies to the Chinese market, invested $3m in CoreBone’s Chinese subsidiary; The Trendlines Group and Agriline (a trust of which Vincent Tchenguiz is a discretionary beneficiary) invested $700k.
The company intends to use the funds for extending its commercial global presence, primarily in China.
Led by CEO Ohad Schwartz, CoreBone develops and sells bioactive bone graft material, providing a natural alternative to synthetic or human and animal-derived (bovine, porcine) bone graft material for dental and orthopedic indications. Corals are grown on Moshav Ein Yahav in the south of Israel, in a closed, controlled aquatic (aquarium) system using proprietary technology and laboratory-made sea water enriched with bioactive nutrients and CoreBone’s own coral breeding source.
https://www.finsmes.com/2021/10/corebone-raises-3-7m-in-funding.html
Sanome Raises £2M in First Funding
Sanome, a London, UK-based health startup, raised £2m in first round of funding.
The round was led by Heal Capital, with participation from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind and a number of high-profile angels including David Cleevely and Pam Garside.
The investment will be used to expand the team across London, Amsterdam, and Cambridge; deliver on key strategic and commercial partnerships to develop and validate the first set of IVD candidates.
Founded by experienced entrepreneurs Benedikt von Thüngen (CEO) and Dr Marc van der Schee (Chief Medical Officer), Sanome has developed a diagnostics innovation engine that combines biomarkers to develop medical grade, at home diagnostic products (IVDs) effectively. The company’s home test are clinically validated to improve patient outcomes and reduce healthcare costs.
Sanome Raises £2M in First Funding
Sanome, a London, UK-based health startup, raised £2m in first round of funding
Medicortex Closes Half Million Euro Pre-IPO Funding Round
Medicortex Finland Oy, a Turku, Finland-based biotechnology company developing diagnostic tests for brain injury, closed a pre-IPO share issue round of half million euro.
Existing shareholders and new investors participated in the round.
The capital will allow the company to proceed to the next phase in the process of Initial Public Offering (IPO) expected to take place in 2022, in parallel to the development of its lead product candidate.
Led by Adrian Harel CEO, Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). The company’s current focus is to develop biomarker diagnostics to evaluate mild TBI and concussion. Its first generation product, ProbTBITM, is a disposable strip test for rapid detection of concussion from urine or saliva, both for professional and lay use.
Medicortex Closes Half Million Euro Pre-IPO Funding Round - FinSMEs
Medicortex Finland Oy, a Turku, Finland-based biotechnology company developing diagnostic tests for brain injury, closed a pre-IPO share issue round of half million euro
iOmx Therapeutics Raises EUR 65M in Series B Funding
iOmx Therapeutics AG, a Martinsried / Munich, Germany-based biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, closed a Series B round totaling EUR 65m.
The round was co-led by Athos Service GmbH – the Strüngmann family office – and MIG Capital AG, with participation from existing investors Wellington Partners, Sofinnova Partners and M Ventures.
The new funds will be invested to advance its lead program IMT-07, to further develop IMT-18, and continue to leverage its target discovery platform, iOTarg, to advance additional novel immune checkpoint programs to lead candidate stage.
Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center and led by Dr. Apollon Papadimitriou, CEO, iOmx Therapeutics is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells.
iOmx Therapeutics Raises EUR 65M in Series B Funding
iOmx Therapeutics AG, a Martinsried / Munich, Germany-based biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, closed a Series B round totaling EUR 65m
Micreos Raises €32M in Funding
Micreos, a The Hague, The Netherlands-based biotechnology company, secured another €32m in funding.
The company intends to use the funds to accelerate clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.
Led by Mark Offerhaus, founder and CEO, Micreos develops new biological therapies based on targeted killing of only unwanted bacteria, set to replace antibiotics in a wide range of applications. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH Zurich.
Micreos Raises €32M in Funding
Micreos, a The Hague, The Netherlands-based biotechnology company, secured another €32m in funding
Expansion Therapeutics Raises $80M in Series B Financing
Expansion Therapeutics, Inc., a Boston, MA-based biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, closed an $80m Series B financing.
The round was led by Cormorant Asset Management with participation from new investors Westlake Village BioPartners, Surveyor Capital (a Citadel company) and Logos Capital as well as Series A investors RA Capital Management, 5AM Ventures, Kleiner Perkins, Sanofi Ventures and Novartis Venture Fund.
Proceeds from the financing will be used to advance the company’s small molecule RNA platform (SMiRNA™) to identify clinical candidates in myotonic dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and various tauopathies.
Led by Renato Skerlj, Ph.D., President and Chief Executive Officer, Expansion Therapeutics is a biotechnology company focused on developing oral medicines for severe RNA-mediated diseases including neurodegenerative disorders. Based on exclusive worldwide rights to research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule RNA modulators. Through this platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of severe RNA-mediated disease indications.
Expansion Therapeutics Raises $80M in Series B Financing - FinSMEs
Expansion Therapeutics, Inc., a Boston, MA-based biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, closed an $80m Series B financing
Membersy Raises $66M in Funding
membersy, an Austin, TX-based digital health company enabling access to quality dental care through subscription-based dentistry, raised $66min funding.
Spectrum Equity made the investment.
The company intends to use the funds to expand product and service offerings.
Led by CEO and Founder Eric Johnson, Membersy is a subscription focused company in the dental industry, providing Dental Service Organizations (DSOs) of all sizes with the tech, marketing, and administration infrastructure to launch and grow a modern membership experience. The platform-as-a-service solution enables DSOs to streamline membership plan marketing and administration to make dental care more approachable while providing dental teams with automated practice onboarding, recurring subscription payments and billing, and real-time analytics to manage and grow their member base.
Membersy Raises $66M in Funding
membersy, an Austin, TX-based digital health company enabling access to quality dental care through subscription-based dentistry, raised $66min funding
Activ Surgical Raises $45M in Series B Funding
Activ Surgical, a Boston, MA-based digital surgery company, raised $45m in Series B financing.
The round was led by Cota Capital, a multi-stage investment firm focused on private and public modern enterprise technology companies, with participation from BAM Funds, Magnetar Capital, Mint Ventures, Castor Ventures, Dream One Vision and NVIDIA.
The company, which has raised a total of $77 in total funding to date, intends to use the funds:
to expand the commercial availability of the ActivInsights software suite, including the first Insight–an AR-based overlay that displays tissue perfusion in real time without the use of traditional dyes,
to extend its commercialization efforts in the U.S.,
to pursue a CE mark in support of the global rollout,
to further enhance the ActivInsights software platform, and
to develop its first ML-based insights.
Led by Todd Usen, CEO, Activ Surgical is a digital surgery company that completed the world’s first autonomous robotic surgery of soft tissue in 2018. The company is building a hardware-agnostic platform, including the recently announced ActivInsights™ augmented reality (AR)-based software suite, to enable autonomous and collaborative surgery through the integration of computer vision, artificial intelligence (AI), machine learning (ML), AR and robotics. Its patent-protected surgical software platform–ActiveEdge™–is being designed to reduce unintended and preventable surgical errors by enhancing a surgeon’s intraoperative decision-making via the aggregation of surgical data from around the world.
Activ Surgical Raises $45M in Series B Funding
Activ Surgical, a Boston, MA-based digital surgery company, raised $45m in Series B financing
Wider Circle Raises $38M in Series B Funding
Wider Circle, a Redwood City, Calif.-based innovative tech-enabled community health organization working with health plans and providers to connect neighbors to manage health, closed a $38m Series B funding.
The round was led by AmeriHealth Caritas, through a new wholly owned subsidiary, Social Determinants of Life, Inc., with participation from Blue Venture Fund, Chicago Ventures and other previous investors.
The company intends to use the funds to build out its national infrastructure, team and technology to support its expansion plans.
Led by Moshe Pinto, CEO, and Darin Buxbaum, president and chief operating officer, Wider Circle works with health plans nationally to deliver unique hyper-local care programs that connect neighbors. The company’s delivery network has been proven to drive resilience, improve member experience and engagement and reduce hospitalizations. Today, Wider Circle offers its innovative programs to more than 320 communities nationwide, including specialized COVID-19 support for vulnerable populations in isolation and peer-to-peer community support.
https://www.finsmes.com/2021/09/wider-circle-raises-38m-in-series-b-funding.html
Kytopen Raises $30M in Series A Funding
Kytopen Corp., a Cambridge, Mass.-based biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, raised $30m in Series A funding.
The round was led by Northpond Ventures, with participation from current investors The Engine, Horizon Ventures, and Mass Ventures, as well as Aldevron Co-Founders Michael Chambers and John Ballantyne and Alexandria Venture Investments. Adam Wieschhaus, Ph.D., CFA, Director at Northpond Ventures, will join the Kytopen board of directors along with Kytopen Co-Founders Paulo Garcia and Cullen Buie and Theresa Tribble, Venture Partner at The Engine.
The company intends to use new capital to commercialize its Flowfect® Tx for cGMP-compliant cell therapy manufacturing and move towards treating the first human patient with Flowfect® engineered cells.
Led by Paulo Garcia, Ph.D., CEO and Co-Founder, Kytopenis advancing the Flowfect® platform, which eliminates the complexity of gene editing and integrates discovery, development, and manufacturing in one flexible and scalable non-viral delivery solution.
